Japan approves second inactivated polio vaccine as it updates policies
This article was originally published in Scrip
After relying for years on the use of live attenuated oral poliomyelitis vaccines in its national inoculation campaigns, Japan has approved its second inactivated product this year, this time as part of a new combined vaccine from Astellas and Kaketsuken.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.